TNFRSF17 and hematologic disorder: Bound T-cells then differentiate and activate, leading to T-cell mediated tumor-specific cytolysis.13 BITEs such as blinatumomab (anti-CD19) and teclistamab (anti-BCMA) have been approved for the treatment of hematologic malignancies; however, developing BITEs for solid tumors has been a more complex endeavor.